Effects of repeated intravenous esketamine administration on affective biases.

Objectives: While neuropsychological effects of conventional antidepressants are well-documented, more research is needed for rapid-acting antidepressants. This study examines the effects of esketamine on emotion processing and cognitive functioning, both acutely and sub-chronically.

Methods: Eighteen treatment-resistant depression (TRD) patients received repeated intravenous esketamine infusions.

Improved gene editing and fluorescent-protein tagging in using a Golden Gate-based CRISPR-Cas9 plasmid system.

CRISPR-Cas9 systems can be used for precise genome editing in filamentous fungi, including . However, current CRISPR-Cas9 systems for rely on relatively complex or multi-step cloning methods to build a plasmid expressing both Cas9 and an sgRNA targeting a genomic locus. In this study we improve on existing plasmid-based CRISPR-Cas9 systems for by creating an extremely simple-to-use CRISPR-Cas9 system for genome editing.

A novel, double Limberg flap repair for recurrent pilonidal sinus disease.

Pilonidal sinuses are chronic inflammation and/or infection of the intergluteal region. Recurrent disease is common and is a source of significant morbidity for affected patients. We present a case of an eighteen-year-old male with extensive recurrent pilonidal disease.

CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial.

The oncofetal antigen Claudin 6 (CLDN6) is highly and specifically expressed in many solid tumors, and could be a promising treatment target. We report dose escalation results from the ongoing phase 1/2 BNT211-01 trial evaluating the safety and feasibility of chimeric antigen receptor (CAR) T cells targeting the CLDN6 with or without a CAR-T cell-amplifying RNA vaccine (CARVac) at two dose levels (DLs) in relapsed/refractory CLDN6-positive solid tumors. The primary endpoints were safety and tolerability, maximum tolerated dose and recommended phase 2 dose (RP2D).